Conduit Pharmaceuticals Inc. Cash Flow-to-Debt Ratio
Conduit Pharmaceuticals Inc. cash flow-to-debt ratio. Conduit Pharmaceuticals Inc. (CDT) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2026, meaning its operating cash flow of $42.74 Million could theoretically repay 0% of its total liabilities ($2.12 Billion) in one year. Check Conduit Pharmaceuticals Inc. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Conduit Pharmaceuticals Inc. (2021–2025)
Cash flow-to-debt ratio of Conduit Pharmaceuticals Inc. from 2021 to 2025. Historical debt coverage capacity for Conduit Pharmaceuticals Inc. across 5 annual periods. Check cash flow reinvestment rate of Conduit Pharmaceuticals Inc. to assess the company's total reinvestment commitment from operating cash flow.
Conduit Pharmaceuticals Inc. Cash Flow-to-Debt Ratio by Year (2021–2025)
Conduit Pharmaceuticals Inc. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Conduit Pharmaceuticals Inc.. For the full cash flow conversion analysis, see Conduit Pharmaceuticals Inc. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.01x | $-15.55 Million | $2.28 Billion | ▲ +99.2% |
| 2024 | -0.88x | $-9.68 Million | $10.99 Million | ▲ +12.4% |
| 2023 | -1.01x | $-7.72 Million | $7.68 Million | ▼ -348.0% |
| 2022 | -0.22x | $-2.27 Million | $10.09 Million | ▲ +98.0% |
| 2021 | -11.17x | $-2.15 Million | $192.51K | — |